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Background: Retreatment TB (tuberculosis) is a serious category of pulmonary TB with a 
treatment outcome that could include MDR-TB (multidrug resistant TB). In the Msukaligwa 
municipality of Mpumalanga Province, South Africa, the burden of TB is high with poor 
treatment outcome indicators, thus creating some preconditions for retreatment TB. 
Knowledge of the characteristics of the patients and related health system factors would help 
in designing interventions to improve the care for patients, the adherence to medication and 
the prevention of retreatment TB.
Aim of the study: The aim was to describe the occurrence, characteristics and management 
outcome of retreatment pulmonary tuberculosis in patients in a TB hospital in Ermelo.
Objectives: The specific objectives were to describe the socio-demographic, behavioural 
and clinical factors related to recurrence of TB in patients; to determine the contribution of 
defaulting treatment to recurrence of TB in the study population; to identify the prevalence of 
resistance to TB medication amongst patients with retreatment TB; and to identify treatment 
outcomes in patients who have been followed up for the duration of retreatment TB.
This study was set in the 58-bed TB hospital in Ermelo.
The study design was cross-sectional and descriptive, and the study population comprised 
of patients admitted with TB at the Ermelo TB hospital between 01 January 2005 and 31 
December 2007. Data were collected from the patients’ medical records and the TB registers 
by using a predesigned form. Data were analysed with Microsoft Excel Spreadsheet at the 
Centre for Statistical Consultation at the University of Stellenbosch.
Results: All of the 388 patient records with retreatment TB, which formed 19.6% of TB 
patients admitted between 2005 and 2007, were reviewed. This comprised 66% male patients 
with a mean age of 41.4, and 34% female patients with a mean age of 35.3. They were mostly 
unemployed, and 93% had a primary education; 43% were unmarried and 34% were married. 
Retreatment TB was diagnosed with sputum smear microscopy in 71%, with a bacilli load of 
3+ in 45% of the patients. Almost three-quarters (74%) of the patients have been afflicted by 
TB, 1–3 years before the episode under study. Retreatment TB categories were: ‘after treatment 
completed’, 69%; ‘default’, 19%; ‘after cure, 8%, and ‘treatment failure’, 4%. The majority, that 
is, 98% (169/172) of patients tested, had a HIV-positive status; the median CD4 cell count was 
106 cells/µL at the time of retreatment, and very few (5%) were on ART (antiretroviral drug 
treatment). Drug resistance to primary TB drugs was as follows: Rifampicin (16%), Isoniazid 
(29%), Ethambutol (19%), and Streptomycin (23%). The treatment outcomes for those for 
whom data were available were: ‘successful’ (49.1%), ‘death’ (23.8%); and ‘treatment default’ 
(22.9%). MDR-TB caused complications in 3.3% of the patients.
Conclusion: The majority of the retreatment TB patients were male patients with an average 
age of 41, and unemployed. More than two-thirds of the patients had completed TB treatment 
previously, and defaulting treatment accounted for less than one-quarter of retreatment 
categories. The process of care was better in terms of the diagnosis of TB with sputum smear. 
Improvement in the documentation of key factors such as smoking, alcohol, drug use amongst 
patients and co-morbidity, as well as counselling and testing for HIV and provision of ARTs, 
is required. Treatment outcomes with regard to successful outcomes should be monitored 
and improved.
© 2011. The Authors.
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Introduction
Tuberculosis (TB) is a major public health problem worldwide, and during 1993 the WHO (World 
Health Organisation)1 has proclaimed it a public health emergency. South Africa is one of the high-
burden countries for TB with an excessive annual estimated incidence.2 The WHO global report on 
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TB in the 2005-estimate, places the incidence of TB in South 
Africa at 245 cases (200–302) per 100 000 population per year, 
and prevalence at 344–718 cases per 100 000 population. It is 
also estimated that mortality caused by TB, varies between 
47 and 107 deaths per 100 000 patients (71/100 000), and that 
the proportion of new adult TB patients of age 15–49 who are 
HIV-positive, is 58% (49% – 65%); new TB patients who are 
multidrug resistant are estimated at 1.8% (1.4% – 2.3%) and 
previously treated TB patients who were multidrug resistant 
in 2002, are estimated at 6.7% (5.5% – 8.1%).2
In the Mpumalanga province of South Africa, the burden 
of tuberculosis reflects the national trend. The incidence of 
TB in the Msukaligwa municipal area is estimated as the 
second highest in the district at about 450 per 100 000.3 The 
available health indicators for 2006 for tuberculosis in the 
Msukaligwa municipal area, indicate a serious problem with 
the following: a Cure Rate of 40%; the Smear Conversion at 
the end of the intensive phase, 35%; and the Defaulter Rate, 
27.5%.3
Improper treatment and default on treatment could 
result in TB bacilli developing resistance to treatment 
with serious consequences for the patient and the general 
population. Patients who present with retreatment 
pulmonary TB represent a group that could eventually 
lead to the development of drug resistance. Understanding 
the characteristics of these patients will help in designing 
interventions that will prevent non-adherence to treatment 
and enhance a high cure rate for patients with TB in the health 
care system, as well as minimise the burden of retreatment 
pulmonary TB on health care facilities and the community.
Setting
The setting of this study is a 58-bed TB hospital in Ermelo, 
Msukaligwa municipality, of the Gert Sibande district of 
Mpumalanga. It is one of the two specialised TB hospitals 
in the district with facilities for the admission of adult TB 
patients. Patients for admission are referred from the one 
regional, the five district hospitals, the primary health care 
clinics, and private doctors, in the Gert Sibande district.
All retreatment TB patients who are ill and live far away 
from the hospital are usually admitted for an initial period 
of 6–8 weeks. During this admission, sputa are collected at 
intervals specified in the National TB Treatment Guidelines 
and the retreatment regimen commences. Decisions on the 
continuation of treatment, sputum culture, drug sensitivity 
and treatment failure are made, depending on the sputum 
smear results at these periods. On discharge, patients can be 
reviewed monthly as outpatients in the hospital, or followed 
up at the nearest primary health care clinics in their area. 
All patients who choose to be followed up at the clinics are 
provided with referral letters for the clinic sister. At the clinic 
they are referred for supervision of treatment under the DOTS 
(Directly Observed Treatment, Short-course) programme 
and will visit the clinic on a monthly basis to collect their 
medication, until the treatment is completed.
Retreatment tuberculosis occurs after a person may, or 
may not, have completed the scheduled treatment course 
for TB. It can occur because of endogenous reactivation or 
exogenous re-infection.4,5 In the South African National TB 
Control Program,6 various categories of retreatment TB have 
been identified. The rates of recurrence of TB has been found 
to vary in various studies from 0% to 14% in one study,7 
whilst a study8 amongst South African miners gave a rate of 
10.3 episodes per 100 person-years at risk during a follow-
up period of 25.1 months. In yet another study,9 a rate of 
18% was indicated. Recurrence was found to be associated 
with poor treatment adherence and occurred after successful 
treatment, as well as after default on treatment.
An episode of retreatment TB could be a consequence 
of a TB relapse or a reinfection with a new TB strain. 
This differentiation can be performed by using DNA 
fingerprinting techniques with Mycobacterium TB.8,9,10,11,12,13,14 
Whether retreatment TB in a patient is due to reinfection or 
reactivation is not clinically distinguishable. The mechanisms 
that have been postulated as leading to the development 
retreatment TB in patients are either endogenous and true 
treatment failure or exogenous reinfection. In an area of 
low TB incidence and low HIV prevalence, studies have 
revealed that reinfection with a new M. tuberculosis strain is 
considered a rare cause of recurrent TB.14,15 This contradicted 
the findings in a population-based retrospective case control 
study16 in Houston, USA, where reinfection with a new strain 
of M. Tuberculosis was the cause of recurrent TB.
In a setting of high TB and HIV prevalence respectively, as 
in South Africa,2 the relative contribution of reinfection or 
relapse to recurrent TB is different. A study10 amongst South 
African mine workers indicated that most recurrent TB was 
due to relapse within 6 months, with reinfection common in 
patients with HIV infection, compared to an earlier study in 
South Africa12 using DNA fingerprinting which provided 
evidence that reinfection was the cause of recurrence of 
tuberculosis.
Non-adherence to TB treatment resulting in retreatment 
TB has been extensively studied, particularly in countries 
with a high burden of TB disease. The factors responsible 
can be categorised under personal (age, gender, marital 
status),17,18,19,20,21,22,23,24 socio-economic or behavioural 
(employment, income, alcohol use),26,27,28,29,30,31,32 co-
morbid,33,34,35,36,37,38 health system,39,40,41 as well as community 
and family related groups. The issues of support from family 
or friends during treatment could reflect community beliefs, 
attitudes and stigma attached to TB and has been found to 
play a crucial role in defaulting.32
Significance of the study
The aim of the study was to describe the occurrence, 
associated factors and management outcomes of retreatment 
pulmonary tuberculosis in patients in the Ermelo TB hospital.
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Ethical considerations
Ethical approval was granted by the Committee for Human 
Research at the University of Stellenbosch and the Research 
Ethics Committee of the Department of Health, Mpumalanga.
Methods
Design and materials
The study design was descriptive. The study population 
comprised of all patients admitted with TB at the TB hospital 
in Ermelo over a 3-year study period. The sample for the 
actual study population comprised all patients aged 15 
and older who have been diagnosed with retreatment TB 
and who have commenced with TB treatment between 01 
January 2005 and 31 December 2007. These are patients who 
have been entered in the hospital-based TB register with 
medical records available in the hospital. Patients excluded 
were those with extra pulmonary TB, and patients with 
retreatment TB who started with treatment in 2004 and 
completed their treatment in 2005.
The required information was extracted from the TB register 
and patients’ medical records and entered into the data 
collection form that was used for each identified patient. The 
data collection form had three-digit serial numbers with no 
patient identifiers on it, but could be cross-referenced with 
the medical record if necessary. Information for analysis was 
derived from the data collection form and entered into the 
Microsoft Excel spreadsheet designed for the analysis.
The reliability of the data collected was assured by clearly 
defining the terms and concepts relevant to the study. For 
this, the case definitions, as contained in the South African 
National TB control programme guidelines, were used. This 
applied to definitions such as ‘retreatment TB’; ‘retreatment 
categories’; ‘treatment outcomes’ and ‘drug resistance’. To 
ensure the validity of the data collected, reference was made 
to each of the patients’ records to ensure that the information 
reflected in the TB register corresponded to the patient’s 
medical record.
Procedure
The data collection involved visits to the Ermelo TB hospital 
during the period of the data collection. The total number 
of patients treated over the study period was ascertained 
from the TB register and patients with retreatment TB were 
identified. Medical records of the patients identified in the 
TB register, were requested in order to extract detailed 
information about each patient, based on the data collection 
tool developed for this purpose.
Analysing
The data were analysed with Microsoft Excel Spreadsheet 
at the Centre for Statistical Consultation, University of 
Stellenbosch. The data collection form served as a guide 
to design the spreadsheet on which data on each of the 
variables contained in the questionnaire were entered, 
and subsequently analysed. This was a descriptive study 
and therefore the data analysis expresses the prevalence 
of various factors associated with retreatment TB using 
summary statistics. The data are presented mainly in the 
form of a histogram chart and tables, reflecting the variables 
of interest to the study.
Definitions
The diagnosis of tuberculosis was considered to be based 
on any of the following: microscopy-sputum smear and 
standard reporting of the bacilli load; clinical evaluation of 
the patient (history, symptoms and signs of illness, and a 
physical examination); and chest radiography interpretation. 
In addition, any patient with TB who was on treatment with 
Regimen 2 was considered to have retreatment TB and in the 
absence of any documentation this was taken as pulmonary 
TB. In order to facilitate the collection of the required data, all 
the definitions applied to the study were those defined in the 
South African TB Control Programme Practical Guidelines 
2000,6 as well as the definitions in national TB register. The 
following are definitions that are relevant to this study.
Retreatment TB Categories
Retreatment TB after treatment completed: the patient 
had completed the course of treatment but no proof of cure 
is provided by the sputum smear test, but the patient now 
smear positive.
Retreatment TB after cure: the patient was treated and 
became smear-negative on completion of the treatment and 
now smear positive.
Retreatment after default or interruption: the patient 
interrupted the initial treatment for 2 or more months. The 
patient may be smear-positive or smear-negative, but still 
has active TB according to clinical or radiological assessment.
Retreatment after failure: The patient is on treatment but 
remained smear-positive 5 months or later after commencing 
TB treatment.
Retreatment TB Outcomes
Cured: the patient is smear-negative at, or 1 month prior, 
to completion of the treatment, and on at least one previous 
occasion.
Completed: the patient has completed the treatment course 
but there is no proof of cure from the sputum test, that is, no 
smear-negative result is available.
Failure: the patient on treatment remained or became smear-
positive 7 months or later after commencing treatment.
Death: the patient died during the course of treatment 
(regardless of the cause of death).
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Default: the patient interrupted the treatment for 2 or more 
months.
Results
A total of 388 patients with retreatment TB were seen at 
the TB Hospital between 2005 and December 2007. These 
constituted 19.6% of the 1980 patients, in total, treated for TB 
during the period. There were 66.0% male and 34.0% female 
patients, with a resulting male : female ratio of 1.9 : 1.The 
mean age for the male patients was 41.4 years and 35.3 years 
for the female patients. For both sexes, the most affected
age group was 35–44 for men, and 25–34 for women (Table 1). 
Ninety-three percent (93.0%) had primary education, 
2.0% had high school education and 6.0% had no formal 
education; 74.7% were unemployed. Information on social 
habits revealed the following: smoking, alcohol and drug 
use was not known for 98% of the patients. With regard to 
marital status, 43.0% were unmarried; in 23.0% the marital 
status was not known; 34.0% were reported as married. The 
following data were available on the number of people in 
the same household, excluding the patient at the time of the 
episode of retreatment TB treatment: the majority (72.0%) of 
the patients lived in households with least 2 persons.
The majority (97.0%) of the patients had TB once in the past 
and 74.0% of these patients had TB in the past 1–3 years 
before the episode under study. With regard to the diagnostic 
process for TB, most of the TB (71.0%) was diagnosed by 
Sputum microscopy (Table 2). The retreatment TB categories 
at the time of diagnosis (Table 3), and information on the drug 
sensitivity testing pattern for the primary TB drugs (Table 4) 
have been reflected. Records were available for analysis for 
about 25.9% (100/386) of the patients. With regard to drug 
sensitivity, more patients (29.0%) were resistant to Isoniazid 
compared to 16.0% for Rifampicin. In terms of treatment 
outcome (Table 5), successful outcomes were 49.1% for 
‘cured and completed treatment’; ‘failure’, 4.2%; ‘default’, 
22.9% and ‘death’, 23.8%, amongst those who were followed 
up at the TB hospital. MDR-TB resulted from 3.3% (7/214) 
of the patients followed up in the hospital. The ‘Treatment 
Outcomes’ for the retreatment TB. MDR-TB is included in the 
Failures. It is a serious complication of retreatment TB and 
not a treatment outcome.
Discussion
Although the proportion of retreatment TB in this study 
may not estimate directly the extent of retreatment TB in the 
population, it, however, gives some indication of the burden 
of this problem on the health system within the context of 
the already high prevalence of TB and HIV diseases in the 
community. It reflects a fair measure of the load of TB patients 
that the health care workers and the institution have to cope 
with. Various studies7,8 have given estimates of retreatment 
TB in the patient population. In a systematic review of long 
term efficacy of DOT regimes7, the rates of retreatment TB 
was found to vary from 0% to 14% after successful treatment 
whilst a study8 amongst South African miners found a rate of 
10.3 episodes per 100 person-years at risk during a follow-up 
of patients for the median period of 25.1 months with most 
recurrence occurring within the first 6 months of follow-
up of patients. This study found that 74% of patients had 
contracted TB, 1–3 years before the current episode, which 
compares with the Malawian47 study that found that 60% of 
patients had another episode of TB within the first 2 years of 
completing treatment.
This study has also revealed some personal factors associated 
with retreatment TB amongst the patients studied. Most 
of the patients with retreatment TB were men with a mean 
age of 41.4 years compared to women who were relatively 
younger at an average age of 35.3 years. The mean age of 
female patients was at least 6.1years less than that of male 
patients. Whilst there have not been consistent findings on the 
effect of gender and default from TB treatment, most studies 
had shown that male patients are more likely to default with 
TB treatment than female patients. This may partly explain 
the relative large proportion of male participants with 
retreatment TB in this study. The finding of this study with 
regard to male patients is similar to others that have been 
reported from studies in Turkey, Nigeria and India. In the 
Turkish study,25 the risk factors for non-successful treatment 
were determined to be retreatment patients older than 46, 
whilst in the Nigerian study,18 the 44.2% who defaulted 
on their treatment were older than 65, and in India,20 not 
completing the process of diagnosis of TB was higher in the 
age group older than 50 years.
The prevalence of behavioural and social factors like 
unemployment, smoking, alcohol and drug use in patients 
TABLE 1: Age and sex distribution of retreatment tuberculosis patients (N =388).
Age Group
Years
Male patients Female patients Total patients
n % n % n %
15–24 6 1.5 15 3.9 21 5.4
25–34 64 16.5 56 14.4 120 30.9
35–44 94 24.2 37 9.5 131 33.8
45–54 64 16.5 20 5.2 84 21.6
55–64 23 5 1.3 28 7.2
≥ 65 4 1.0 0 0.0 4 1.0
Total 255 65.7 133 34.3 388 100
Source: Authors’ Original data
N, The total number of patients; n, Given as a means of number.
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with retreatment TB has also emerged from the study. 
Seventy five per cent of the study population indicated that 
they were unemployed at the time of treatment. This is the 
only social factor that was found in the study and compares 
well with what has been reported in studies in other parts 
of the world like Nepal, Russia and Brazil26,27,28 as one of the 
reasons for defaulting on TB treatment, which resulted in 
retreatment TB. There were little data on smoking, alcohol 
and drug use as it was not documented in the records. This 
is an important omission in the process of care of these 
patients which should be remedied and it should be realised 
that there is some linkage between these social habits and 
retreatment TB.
There was some limited information on the HIV status of 
the patients with retreatment TB. Information on the HIV 
status was available for only 44.2% of the patients in this 
study (Figure 1). This low proportion could be related to the 
lack of capacity to offer voluntary counselling and testing 
to all patients and recording the results in the patients’ files. 
Amongst those who were tested, data indicate that 98.3% 
were HIV-positive. A previous study34 amongst South African 
miners has indicated that HIV infection was associated with 
significantly increased rates of recurrent TB with an incidence 
of 8.2 per 100 person-years in HIV-positive compared to 2.2 
per 100 person-years in HIV-negative men. The need to test 
patients is recognised in the hospital; however, patients can 
decline after voluntary counselling.
Another HIV-related factor to the recurrence of TB is the 
level of immune-compromise as reflected by the CD4 counts. 
Information on this was available for a very small number 
of patients. Other studies48,49 have showed that the risk 
of developing recurrent TB is increased as the immunity 
worsens with declining CD4 counts. In this study, the median 
CD4 count for those that were available was low at 106 cells/
µL. The use of ART was found to be very limited in the study 
patient population. This was not unexpected as the roll out of 
ART in public sector was only initiated within the period of 
the study, hence most of those HIV-positive patients at that 
time did not have access to such services.
The study also revealed information on drug sensitivity 
patterns amongst patients. There was a large proportion 
of non-documentation relating to drug resistance and 
sensitivity to TB drugs used, as data was only available for 
25.9% (100/386) of the patients studied. The low proportion 
of sensitivity testing reflects a serious lack of attention to 
this aspect of the care process for TB patients with regard 
to documentation in the patient files. The drug resistance 
to primary TB drugs varied from 16% for Rifampicin to 
29% for Isoniazid. The level of resistance to any of the TB 
drugs is high when compared to other reported studies from 
Saudi Arabia42 and South Africa.43,44,45,46 The findings of this 
study underlines the fact that resistance to any TB drug is 
significantly more probable in patients with retreatment 
pulmonary TB. The significance of this resistance lies in 
TABLE 2: Distribution of retreatment tuberculosis patients according to how 
tuberculosis was first diagnosed (N =388).
Main Diagnostic tool n %
Sputum AFB 276 71.1
Chest X-Ray 93 24.0
Others (Pleural fluid ADA) 19 4.9
Source: Authors’ Original data
N, The total number of patients; n, Given as a means of number; AFB, Acid-fast bacilli; ADA, 
Adenosine deaminase.
TABLE 3: Distribution of Retreatment tuberculosis patients by retreatment 
tuberculosis category based on previous tuberculosis episode (N = 388).
Retreatment TB Category n %
After treatment completed 266 69
After cure 31 8
After default 75 19
After failure 16 4
Source: Authors’ Original data
N, The total number of patients; n, Given as a means of number; TB, tuberculosis.
TABLE 4: Distribution of retreatment tuberculosis patients by drug sensitivity testing profile.
Drug N n† n‡ Sensitive % Resistant %
Rifampicin 386 286 100 84 84.0 16 16.0
Isoniazid 387 287 100 71 71.0 29 29.0
Ethambutol 387 288 99 80 80.8 19 19.1
Streptomycin 387 288 99 76 76.7 23 23.2
Source: Authors’ Original data
N, The total number of patients; n, Given as a means of number. 
†, Number of patients not tested. 
‡, Number of patients tested.
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FIGURE 1: Distribution of retreatment TB patients by HIV status (N = 388).
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the potential for the emergence of multidrug resistance TB 
which is an important and serious unsuccessful outcome of 
retreatment TB.
The outcomes of retreatment TB in this study are only for 
those who were seen at the TB hospital and followed up on 
discharge. Those who defaulted on their treatment were those 
who were followed up as outpatients in the hospital after the 
initial phase of treatment. According to WHO,2 the targets 
of TB programs for new PTB patients are smear-positive 
detection rates of 70% and a cure rate of 85%. Whilst no 
specific targets for the outcomes have been set for retreatment 
TB, it would be logical to assume that they should not be 
less than for new TB cases. In terms of the smear-positive 
detection rate, the TB programme at the hospital has been 
managed competently. It achieved 71% compared with the 
WHO-set target of 70%, because the TB patients were mostly 
diagnosed with sputum smear microscopy. The treatment 
outcomes (cured and completed treatment) together were 
found to be 49.1%. This is much less than the 73% reported 
by WHO in its 2005 global review of TB programmes. Of 
great significance is the 3.3% MDR-TB found in this study. 
The MDR-TB is very expensive to treat and the longer 
treatment duration makes it difficult for patients to adhere 
to treatment. This proportion does not, however, derive from 
the estimated proportion of TB cases that were treated during 
the period which will lower the overall proportion. Amongst 
new TB cases in South Africa, previous studies had shown 
the MDR-TB rate to be relatively low at 1.6%, whilst that for 
retreatment TB was 6.6% (4.0%–13.9%).31 Compared to this, 
our figure of 3.3% for the retreatment TB cases is relatively 
small. This should, however, be seen against the setting that 
about 44% of the retreatment TB patients were transferred to 
other facilities for which information on outcomes was not 
available.
Limitations of the study
The study is limited by its design which is mainly descriptive 
and retrospective in nature. The study relies on the previously 
collected data and information on the patient file for analysis. 
Some of the information was incomplete, thus making it 
difficult to have a complete perspective of the problem under 
study. In situations where the diagnosis of TB was based 
on the chest radiograph, this information was accepted as 
it was recorded and the study did not seek to look at the 
chest radiograph in question. The treatment outcomes of 
patients discharged from the TB hospital and followed up at 
the clinics were not ascertained because of limited resources 
available to the researcher to visit the clinics and to collect 
the data needed.
The study is further limited by the fact that there is no control 
or comparison group on which to make an in-depth analytical 
appraisal of the identified related factors of retreatment TB. 
Time and resources had not made this possible. This aspect 
should be explored in a future study.
Recommendations
All TB patients (new or retreatment TB) should be offered 
voluntary counselling and testing for HIV, consistently. 
Those who are HIV-positive should be enrolled into 
ART programmes and monitored regularly to detect 
any deterioration in their immune status by regular CD4 
measurements and necessary intervention should be started.
Improve process of care by appropriate and complete 
documentation in the patient file of all potential factors 
impacting on retreatment TB at the time of admission into the 
treatment programme and any new developments reviewed 
and updated as situations develop in the patients over the 
period of care. This will provide sufficient data on which 
the burden of the problem could be understood and allow 
dominant factors identified to be addressed with relevant 
interventions. Strengthening the institutional capacity to 
do this will be required in terms of personnel and other 
resources for monitoring and reporting on outcomes for 
retreatment TB patients.
Further researches should be undertaken that involve data 
collection from the patients, family and treatment partners 
directly, using quantitative and qualitative approaches to 
allow for quantitative analyses of factors and test associations 
with retreatment TB.
Conclusion
This study has confirmed that some factors related to 
retreatment TB are similar to what were obtained elsewhere. 
In our situation majority of patients had completed TB 
treatment previously and default from treatment accounted 
for less than one quarter of the patients. There was a large 
proportion of non-documentation relating to drug resistance 
and sensitivity to TB drugs which reflects a serious lack of 
attention to this aspect of the care process for TB patients. 
The treatment outcomes (cured and completed treatment) 
together, were found to be much less than the reported 
target for TB programmes. For those tested for HIV, they 
were overwhelmingly positive. The quality of care for 
these patients needs to be improved by paying attention 
and documenting these factors. This study opens up areas 
of further research in our setting to test associations and 
prominence of some of the identified factors.
TABLE 5: Distribution of retreatment tuberculosis patients by treatment 
outcome for patients followed up at the hospital (N = 214*).
Treatment Outcome n %
Cured 19 8.9
Completed Treatment 86 40.2
Failure† 9 4.2
Defaulted 49 2.9
Death 51 23.8
Source: Authors’ Original data
N, The total number of patients; n, Given as a means of number.
*, (44.8% [174/388] patients were transferred to the clinics and records were not available 
for review).
†, Includes patients with MDR-TB (n = 7), MDR-TB rate of 3.3%.
MDR, multidrug resistant.
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